So far it appears that ARNA has avoided the myriad of management blunders of VVUS, though I'm not fully sure that the management team could have foreseen them and avoided them. Still, the ARNA approach to partner with Eisai, getting the drug into all the local pharmacies, keeping the EU option alive, it all seems to be working.
Now if the DEA would just finish the final classification, we could get to work.
Arna has a sales force who are being trained, it has a partner who has contributed lots of cash, it has a product that is safer and will be made in Switzerland, it can advertise its product...how about that for starters in avoiding the missteps of Vvus
Both Co have well trained sales forces and both have plenty of cash. ARNA is not going to advertise its product initially per the ARNA President in his last public comments. He said it is a go slow train the Dr's marketing approach initially. That is exactally what VVUS has done. VVUS is having a REMS change in place allowing retail drug store sales starting April 28 per their CC.The only apparant difference is B will be manufactured in Europe and Q is made in the US. How does that matter in making a pill?